Mobile

Dovigist : Phase II trial to evaluate the treatment benefits and the safety of the new investigational medicine Dovitinib (TKI258) in patients with specific cancers in the gastrointestinal tract whi...

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-001725-24

Dovigist : Phase II trial to evaluate the treatment benefits and the safety of the new investigational medicine Dovitinib (TKI258) in patients with specific cancers in the gastrointestinal tract which do not respond any more to the currently established standard treatment imatinib or can not be treated any more with imatinib because of intolerance

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the antitumor activity of Dovitinib (TKI258) in terms of disease control rate (DCR): CR+PR+SD, at 12 weeks in adult patients with documented disease progression while on therapy with imatinib for unresectable and/or metastatic GIST, recurrent GIST on adjuvant imatinib or within the first 3 months after discontinuation of adjuvant imatinib or, unresectable and/or metastatic GIST intolerant to imatinib

Critère d'inclusion

  • Unresectable, metastatic or recurrent gastrointestinal stromal tumor (GIST)

Liens